Trial Profile
A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients With Known or Suspected Focal Liver Lesions and Severe Renal Impairment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs CMC 001 (Primary) ; Alanine; Colecalciferol; Manganese chloride
- Indications Liver disorders; Renal impairment
- Focus Diagnostic use; Registrational
- Acronyms SPARKLE
- Sponsors Ascelia Pharma
- 09 Feb 2024 According to an Ascelia Pharma media release, company starts image reading phase and re-confirms Phase 3 SPARKLE results by May 2024.
- 18 Aug 2023 According to an Ascelia Pharma media release, the company reported the need for a re-evaluation of the collected images from this study. Clarification that the images were not read and scored properly. Preparations for the re-evaluation are already underway, and we will communicate the timeline and financial implications for this mid-September.
- 09 Aug 2023 According to an Ascelia Pharma media release, the company provides clarifications around the intra-reader variability in read-out of images in the SPARKLE study